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Corneal endothelial cells play a crucial role in main-
taining corneal transparency. Corneal clarity requires a
net movement of fluid from corneal stroma to aqueous
humor [1]. The efficiency of flux depends on undam-
aged cells and cellular density. Any factor that
decreases the cellular density in corneal endothelium
may reduce the efficiency of corneal pump function
and transparency.
Many antiglaucoma drugs have been developed
for the treatment of glaucoma patients. It is now 
recognized that glaucoma is a chronic disease caused
by the death and subsequent loss of ganglion cells and
their axons in the optic nerve [2]. Many glaucoma
patients need to have antiglaucoma drug administra-
tion for a long time until the intraocular pressure is
well controlled by laser therapy or surgery such as
trabeculectomy. Under this circumstance, the corneal
endothelium is continuously soaked in antiglaucoma
drugs over a long period of time. The physiologic
function of corneal endothelial cells may be changed
gradually in the process of drug administration.
Some evidence indicates that loss of corneal endo-
thelial cells occurs with long-term topical epinephrine
therapy in glaucoma patients [3]. The mean percentage
loss in endothelial cell density from baseline was
3.6%, 4.5% and 4.2%, respectively, for the dorzola-
mide, timolol and betaxolol treated groups on human
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In this study, the various antiglaucoma drugs including betaxolol, timolol, levobunolol, carteolol,
brimonidine, dipivefrin, dorzolamide, brinzolamide, latanoprost, unoprostone, and pilocarpine
were used to investigate the effects of cellular cytotoxicity in cultured bovine corneal endothelial
cells. After exposure to the drugs in three dilutions, 1/100, 1/1,000, and 1/10,000, for 100 minutes,
cells were estimated based on the release assay of lactate dehydrogenase (LDH) enzyme. It was
found that cellular LDH was significantly released in the medium only at 1/100th dilution of
betaxolol, brimonidine, dorzolamide, dipivefrin, latanoprost and unoprostone to 130%, 123%,
145%, 157%, 128% and 237%, respectively, compared with controls upon exposure to drugs for 100
minutes. Moreover, benzalkonium chloride preservative at the concentrations ranging from 0.001
to 0.00001 mg/mL did not affect cellular LDH release in bovine corneal endothelial cells. These
results indicate that high concentrations of antiglaucoma drugs may induce cytotoxicity 
in corneal endothelial cells.
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corneas after 1 year of treatment [4]. Thus, it is crucial
to know which commercial antiglaucoma drugs cause
corneal endothelial cell damage. Although many
antiglaucoma drugs are available for clinical use, the
effects of these drugs on corneal endothelial cells
have been poorly investigated. In this study, we com-
pared the effects of various commercial antiglaucoma
drugs including betaxolol, timolol, levobunolol, car-
teolol, brimonidine, dipivefrin, dorzolamide, brinzol-
amide, latanoprost, unoprostone, and pilocarpine on
cellular cytotoxicity in cultured corneal endothelial cells
with assay of medium lactate dehydrogenase (LDH),
which is a stable cytosolic enzyme that is released
upon cell lysis.
MATERIALS AND METHODS
Materials
Culture mediums include trypsin, essential minimal
essential medium (EMEM), glutamine, gentamicin, and
fetal bovine serum were obtained from GIBCO (Grand
Island, NY, USA). Commercially available antiglau-
coma drugs such as 0.5% (16.2mM) betaxolol (Betoptic,
Alcon, containing 0.1mg/mL benzalkonium chloride),
0.25% (5.8 mM) timolol (Timoptol, Merck Sharp &
Dohme-Chibret, containing 0.048 mg/mL benzalko-
nium chloride), 0.5% (17.1mM) levobunolol (Bunolgan,
Allergan, containing 0.04 mg/mL benzalkonium chlo-
ride), 1% (68 mM) carteolol (Arteoptic, Otsuka, con-
taining 0.005 mg/mL benzalkonium chloride), 0.2%
(6.8 mM) brimonidine (Alphagan, Allergan, containing
0.01 mg/mL benzalkonium chloride), 0.1% (2.8 mM)
dipivefrin (Propine, Allergan, containing 0.04 mg/mL
benzalkonium chloride), 2% (61.6 mM) dorzolamide
(Trusopt, Merck Sharp & Dohme-Chibret, containing
0.075 mg/mL benzalkonium chloride), 1% (26 mM)
brinzolamide (Azopt, Alcon, containing 0.1 mg/mL
benzalkonium chloride), 0.005% (0.11 mM) latanoprost
(Xalatan, Pharmacia & Upjohn, containing 0.08mg/mL
benzalkonium chloride), 0.12% (2.82 mM) unopros-
tone (Rescula, Fujisawa, containing 0.015 mg/mL ben-
zalkonium chloride), and 1% (40.8 mM) pilocarpine
(Spersacarpine, Dispersa, containing 0.1 mg/mL ben-
zalkonium chloride) were diluted with serum-free
medium to make three dilutions of 1/100, 1/1,000, and
1/10,000. Benzalkonium chloride was purchased from
Sigma Chemical (St. Louis, MO, USA). The LDH kit
(CytoTox 96R Non-Radioactive Cytotoxicity Assay)
was obtained from Promega Corporation (Madison,
WI, USA). All other chemicals were obtained from
Merck (Darmstadt, Germany).
Culture of bovine corneal endothelial cells
BCE C/D-1b cells, a stable cell line derived from bovine
corneal endothelium, were obtained from American
Type Culture Collection (CRL-2048; Rockville, MD,
USA). Cells were grown in minimal essential medium
(MEM) containing 20% fetal bovine serum, 3.8 mM 
L-glutamine, and 50 μg/mL gentamicin following
previously published procedures [5,6]. The cultures
were kept in a humidified chamber at 5% CO2
and 37°C, and the medium was changed every 2 or 
3 days.
Measurement of LDH release from cells
To evaluate cellular damage in the presence of drug
treatment, LDH release from cells into the medium
was assayed following the manufacturer’s guidelines
included in the kit (CytoTox 96R Non-Radioactive
Cytotoxicity Assay; Promega Corp.). Cultured corneal
endothelial cells with 4,000 cells/well were seeded 
in 96-well culture plates and allowed to settle for 
24 hours to form a monolayer. The cells in each well
were exposed to 150 μL of serum-free MEM con-
taining various antiglaucoma drugs at three dilutions
of 1/100, 1/1,000, and 1/10,000 with serum-free
medium for 100 minutes at 37°C. After drug expo-
sure, 50 μL of supernatant from each well was 
transferred to new 96-well culture plates. Then, super-
natant was incubated with 50 μL of substrate mix
solution at room temperature for 30 minutes and
kept away from light. After the addition of 50 μL
stop solution, the optical density of the fluid in 
each well was read at 490 nm in a multiwell spec-
trophotometer (Titertek Multiscan, Flow Lab,
Scotland, UK). LDH release was calculated based on
the difference in optical density between the treat-
ment and control groups with the value of serum-
free medium subtracted. The values obtained from
control cells were recorded as 100%. Results are
expressed as a percentage of those in corresponding
control cells.
Statistical analysis
All data were analyzed with ANOVA followed by
comparison with Dunnett’s test. The values were
presented as mean ± SEM from three experiments
with triplicate determinations. The values were 
considered to be significantly different from correspon-
ding controls when p < 0.05. Control values were set
as 100% response.
RESULTS
To determine the effects of antiglaucoma drugs on
cellular cytotoxicity, LDH release was assayed after
corneal endothelial cells were exposed to various
antiglaucoma drugs in three dilutions of 1/100,
1/1,000, and 1/10,000 for 100 minutes. Drug-induced
LDH release in the medium was increased in the
presence of the 1/100 dilution of six drugs: betaxolol,
brimonidine, dorzolamide, dipivefrin, latanoprost and
unoprostone. Following pretreatment of cells with
selective β1-adrenergic antagonist betaxolol at 1.62,
16.2, and 162 μM for 100 minutes, the value of LDH
in the medium significantly increased only at 162 μM
to 130 ± 5% when compared with the value of the 
corresponding control (Figure 1). After addition of
α2-agonist brimonidine at 0.68, 6.8, and 68.0 μM for
100 minutes, the LDH value in medium was signifi-
cantly increased only at the concentration of 68.0 μM
to 123 ± 4% in comparison with the control group
(Figure 2). After treatment of the cells with three 
dilutions of dorzolamide at 6.16, 61.6, and 616 μM 
for 100 minutes, the LDH value in the medium sig-
nificantly increased only at 616 μM to 145 ± 5% in
comparison with the control group (Figure 3). For the
sympathomimetic drug dipivefrin, only the 1/100
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Figure 1. Effects of betaxolol on lactate dehydrogenase (LDH)
release from cultured bovine corneal endothelial cells. Cells were
exposed to betaxolol at concentrations of 162, 16.2 and 1.62mM
for 100 minutes. All data are presented as percentage of control
from three separate experiments. Individual experiments were car-
ried out in triplicate. Data are mean ± SEM. *p < 0.05 compared
with control.
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Figure 2. Effects of brimonidine on lactate dehydrogenase (LDH)
release from cultured bovine corneal endothelial cells. Cells were
exposed to brimonidine at concentrations of 68, 6.8 and 0.68mM
for 100 minutes. All data are presented as percentage of control
from three separate experiments. Individual experiments were car-
ried out in triplicate. Data are mean ± SEM. *p < 0.05 compared
with control.
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Figure 3. Effects of dorzolamide on lactate dehydrogenase (LDH)
release from cultured bovine corneal endothelial cells. Cells were
exposed to dorzolamide at concentrations of 616, 61.6 and 6.16mM
for 100 minutes. All data are presented as percentage of control
from three separate experiments. Individual experiments were car-
ried out in triplicate. Data are mean ± SEM. *p < 0.05 compared
with control.
dilution (28 μM) increased LDH release significantly
to 157 ± 4% compared to the corresponding controls
(Figure 4). Of the three concentrations of latanoprost
(1.1, 0.11, 0.01 μM), only 1.1 μM increased LDH release
significantly to 128 ± 5% in comparison with controls
(Figure 5). When cells were exposed to the  synthetic
docosanoid unoprostone for 100 minutes, the LDH
value in the medium significantly increased only at
31 μM to 237 ± 8% compared with corresponding con-
trols (Figure 6). In this study, we found that LDH 
values were not induced to increase by the other drugs
(timolol, levobunolol, carteolol, brinzolamide, pilo-
carpine) at any dilution (data not shown).
All of the commercial antiglaucoma drugs tested
contain benzalkonium chloride as a preservative. To
estimate the effect of benzalkonium chloride on
corneal endothelial cells, we also tested various concen-
trations of benzalkonium chloride, 0.001, 0.0001 and
0.00001 mg/mL, on LDH release. The results demon-
strated that no statistical difference was found between
the three concentrations of benzalkonium chloride
and the corresponding controls on LDH release (data
not shown).
DISCUSSION
Although many antiglaucoma drugs have been admin-
istered in glaucoma patients with the distinct mecha-
nism of lowering intraocular pressure, the comparison
of the cytotoxic effects of the various antiglaucoma
drugs is not well characterized. In this study, we
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Figure 4. Effects of dipivefrin on lactate dehydrogenase (LDH)
release in cultured bovine corneal endothelial cells. Cells were
exposed to dipivefrin at concentrations of 28, 2.8 and 0.28mM for
100 minutes. All data are presented as percentage of control from
three separate experiments. Individual experiments were carried
out in triplicate. Data are mean ± SEM. *p < 0.05 compared with
control.
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Figure 5. Effects of latanoprost on lactate dehydrogenase (LDH)
release in cultured bovine corneal endothelial cells. Cells were
exposed to latanoprost at concentrations of 1.1, 0.11 and 0.01mM
for 100 minutes. All data are presented as percentage of control
from three separate experiments. Individual experiments were car-
ried out in triplicate. Data are mean ± SEM. *p < 0.05 compared
with control.
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Figure 6. Effects of unoprostone on lactate dehydrogenase (LDH)
release in cultured bovine corneal endothelial cells. Cells were
exposed to unoprostone at concentrations of 31, 3.1 and 0.31mM
for 100 minutes. All data are presented as percentage of control
from three separate experiments. Individual experiments were car-
ried out in triplicate. Data are mean ± SEM. *p < 0.05 compared
with control.
compared the cellular cytotoxicity of various commer-
cial antiglaucoma drugs on corneal endothelial cells
under similar culture conditions. We found that 1/100
dilution of betaxolol, brimonidine, dipivefrin, dorzo-
lamide, latanoprost and unoprostone can cause corneal
endothelial cellular damage after 100 minutes of incu-
bation. The most potent effect of drug-induced LDH
release was displayed by unoprostone.
Corneal endothelial cells play a crucial role in
maintaining corneal transparency [1]. Under condi-
tions such as surgery or disease, excessive cellular
damage may impair the ability of the endothelium to
act effectively as a barrier to fluid flow from the aque-
ous humor to the stroma [7,8]. This loss of endothe-
lial function may bring about corneal edema and
decrease in visual acuity. There is evidence to show
that some antiglaucoma drugs may damage or inter-
fere with the normal physiologic functions of corneal
endothelium [3]. After the administration of dorzol-
amide, timolol and betaxolol for 1 year, the loss in
endothelial cell density was 3.6%, 4.5% and 4.2%,
respectively, compared with cell density at baseline
[4]. Dipivefrin has been shown to inhibit the growth
of corneal endothelial cells [9]. As to normal function,
timolol and betaxolol have been shown to inhibit the
activity of Na+K+-ATPase in corneal endothelial cells
[10]. Dorzolamide also significantly inhibits carbonic
anhydrase activity in corneal endothelial cells [11].
Although we found that the six drugs betaxolol, bri-
monidine, dorzolamide, dipivefrin, latanoprost and
unoprostone induced cellular LDH release at 1/100
dilution, the identification of various drugs on cellu-
lar target sites in corneal endothelial cells remains to
be investigated.
According to the pharmacokinetic assay of latano-
prost, the maximum concentration of active latanoprost
is detected in the aqueous humor within 1–2 hours
amounting to approximately 10–7 M after topical
administration of the clinical dose of 10–4 M in
humans [12]. The elimination half-life of latanoprost
in the cornea has been determined to be 1.8 hours 
in rabbits [13]. Thus, we estimated the effect of
antiglaucoma drugs on corneal endothelial cells with
concentrations starting from 1/100 dilution of the
original commercial concentrations for an exposure
of 100 minutes.
In summary, the results reported here provide evi-
dence to indicate that some antiglaucoma drugs may
cause cytotoxicity to corneal endothelial cells and
gradually interfere with normal corneal function.
Moreover, after intraocular surgery, the damaged
corneal endothelium in glaucoma patients who have
been treated with cytotoxic antiglaucoma drugs may
take more time to recover to normal corneal clarity
compared to that in glaucoma patients who have been
treated with noncytotoxic drugs. Thus, the long-term
use of these drugs may need to be carefully monitored
for changes in corneal endothelium.
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